FDA Approves LEQEMBI IQLIK for At-Home Alzheimer’s Maintenance Therapy

Alzheimer’s disease (AD) is a progressive neurodegenerative disorder characterized by amyloid-beta (Aβ) accumulation, including toxic protofibrils, driving cognitive decline in patients with mild cognitive impairment (MCI) or mild dementia. Maintenance therapy is critical to sustain clinical benefits after initial treatment, yet accessible options are limited. Lecanemab, a monoclonal antibody targeting Aβ aggregates, has shown efficacy in slowing AD progression, but IV administration poses logistical challenges. The objective is to evaluate the efficacy, safety, and usability of LEQEMBI IQLIK (lecanemab-irmb), a subcutaneous autoinjector for weekly maintenance dosing in early AD, following 18 months of IV initiation therapy.

Updated ACP Guidelines on Preventing Episodic Migraines

The American College of Physicians (ACP) has issued new guidelines to prevent episodic migraines among adults, specifically for primary care physicians who see patients who are not taking preventive migraine drugs previously.

Liraglutide Offers Hope for Better Outcomes After Stroke in Diabetes Patients

A new study, reported at the International Stroke Conference, indicates that a medication called liraglutide, which is often used for diabetes under the brand names Victoza and Saxenda, can benefit patients who’ve had mini-strokes or transient ischemic attacks (TIAs) and have diabetes.

Mirdametinib Gains FDA Nod for NF1-PN

The FDA approved mirdametinib (Gomekli) for adults and children 2 years and older with neurofibromatosis type 1 (NF1) and symptomatic plexiform neurofibromas (PN) that are not resectable surgically.